July Newsletter Summary from Delta Gastroenterology
In this month’s newsletter, we’re focusing on something that affects many of our patients — and that’s liver health, especially for those living with type 2 diabetes or prediabetes.
You may not have heard of MASLD (Metabolic dysfunction–Associated Steatotic Liver Disease), but nearly 70% of people with type 2 diabetes have it. You might know it by its old name: fatty liver disease. If it’s left untreated, MASLD can progress into a more serious condition called MASH, which can lead to inflammation, liver scarring, cirrhosis, liver failure, or cancer.
The big news? The American Diabetes Association (ADA) now officially recognizes the liver as a target organ in diabetes care. That means liver health should be a routine part of how we manage diabetes — and that’s exactly what we’re doing here at Delta Gastro.
We’ve already taken steps to put this new guidance into practice for you:
We calculate your FIB-4 liver risk score annually
We provide customized nutrition and lifestyle counseling
We evaluate medications that support both liver and metabolic health
And we offer direct referrals to our hepatology team for advanced care when needed
Our goal is simple: catch liver disease early, prevent serious complications, and help you live a longer, healthier life.
If you or someone you care about is managing diabetes or prediabetes, let’s talk about your liver health. We’re here to help you stay ahead of the curve — and in control of your health.
Download July Newsletter PDF